hiv

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Sciences Inc. (NASDAQ: GILD) reported its first quarter financial results after market close on Tuesday and missed analysts estimates. Shares fell by 7 percent after the opening bell on Wednesday.For the first quarter, Gilead reported revenue..

Endo to Remove Opioid Painkiller in U.S. After FDA Request

Endo to Remove Opioid Painkiller in U.S. After FDA Request

Endo International Plc. (NASDAQ: ENDP) announced on Thursday that it will voluntarily remove its powerful opioid painkiller, Opana ER, a month after the U.S. Food and Drug Administration's withdrawal request amid the growing opioid abuse crisis ..